Bufalin: A Systematic Review of Research Hotspots and Antitumor Mechanisms by Text Mining and Bioinformatics
- PMID: 33148004
- DOI: 10.1142/S0192415X20500810
Bufalin: A Systematic Review of Research Hotspots and Antitumor Mechanisms by Text Mining and Bioinformatics
Abstract
Bufalin is an anticancer drug extract from traditional Chinese medicine. Several articles about bufalin have been published. However, the literature on bufalin has not yet been systematically studied. This study aimed to identify the study status and knowledge structures of bufalin and to summarize the antitumor mechanism. Data were retrieved and downloaded from the PubMed database. The softwares of BICOMB, gCLUTO, Ucinet 6.0, and NetDraw2.084 were used to analyze these publications. The bufalin related genes were recognized and tagged by ABNER software. Then these BF-related genes were performed by Gene Ontology (GO) enrichment analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways analysis, and protein-protein interaction (PPI) network analysis. A total of 474 papers met the search criteria from 2000 to 2019. By biclustering clustering analysis, the 50 high-frequency main MeSH terms/subheadings were classified into 5 clusters. The clusters of drug therapy and the mechanism of bufalin were hotspot topics. A total of 50 genes were identified as BF-related genes. PPI network analysis showed that inducing apoptosis was the main effect of bufalin, and apoptosis-related gene Caspase 3 was the most reported by people. Bufalin could inhibit the proliferation, invasion, and metastasis of cancer cells through multiple signaling pathways, such as PI3K/AKT, Hedgehog, MAPK/JNK, Wnt/[Formula: see text]-catenin, TGF-[Formula: see text]/Smad, Integrin signaling pathway, and NF-KB signaling pathway via KEGG analysis. Through the quantitative analysis of bufalin literature, we revealed the research status and hot spots in this field and provided some guidance for further research.
Keywords: Anticancer Effect; Bibliometrics; Bioinformatics; Bufalin; Review; Signaling Pathway.
Similar articles
-
PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells.Anticancer Drugs. 2009 Jan;20(1):59-64. doi: 10.1097/CAD.0b013e3283160fd6. Anticancer Drugs. 2009. PMID: 19343001
-
Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.Oncotarget. 2016 Apr 12;7(15):20193-208. doi: 10.18632/oncotarget.7935. Oncotarget. 2016. PMID: 26958938 Free PMC article.
-
Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.J Ethnopharmacol. 2016 Dec 4;193:538-545. doi: 10.1016/j.jep.2016.09.047. Epub 2016 Sep 28. J Ethnopharmacol. 2016. PMID: 27686271
-
Exploration of mechanism of Bufalin and Bufalin derivatives in hepatocellular carcinoma.Phytomedicine. 2025 Jun;141:156686. doi: 10.1016/j.phymed.2025.156686. Epub 2025 Mar 26. Phytomedicine. 2025. PMID: 40220402 Review.
-
Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients.Asian Pac J Cancer Prev. 2012;13(11):5339-43. doi: 10.7314/apjcp.2012.13.11.5339. Asian Pac J Cancer Prev. 2012. PMID: 23317181 Review.
Cited by
-
Global Trends in Atherosclerosis Research in the Epigenetics Field: Bibliometric and Visualization Studies.Int J Environ Res Public Health. 2021 Dec 13;18(24):13154. doi: 10.3390/ijerph182413154. Int J Environ Res Public Health. 2021. PMID: 34948764 Free PMC article.
-
Effects of dihydroartemisinin, a metabolite of artemisinin, on colon cancer chemoprevention and adaptive immune regulation.Mol Biol Rep. 2022 Apr;49(4):2695-2709. doi: 10.1007/s11033-021-07079-1. Epub 2022 Jan 18. Mol Biol Rep. 2022. PMID: 35040004
-
An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives.Front Pharmacol. 2023 Oct 4;14:1274336. doi: 10.3389/fphar.2023.1274336. eCollection 2023. Front Pharmacol. 2023. PMID: 37860119 Free PMC article. Review.
-
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.J Exp Clin Cancer Res. 2022 Jan 6;41(1):11. doi: 10.1186/s13046-021-02220-1. J Exp Clin Cancer Res. 2022. PMID: 34991674 Free PMC article.
-
Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions.Front Chem. 2023 Mar 16;11:1137547. doi: 10.3389/fchem.2023.1137547. eCollection 2023. Front Chem. 2023. PMID: 37007051 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous